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Structured Summary (Word Count: 250) 30 
Background: Non-alcoholic fatty liver disease (NAFLD) is common among people living with 31 
HIV. There is limited data available on the pathophysiology of NAFLD and the development of 32 
fibrosis in this population. 33 
Objectives: to investigate the association of bacterial translocation, adipose tissue 34 
dysfunction, monocyte activation and gut dysbiosis in patients with HIV mono-infection and 35 
NAFLD. 36 
Methods: Cases with biopsy-proven NAFLD and HIV mono-infection were age and sex-37 
matched to HIV+ and HIV- controls. Markers of bacterial translocation (lipopolysaccharide-38 
binding protein (LBP), bacterial DNA and lipopolysaccharide (LPS)), adipose tissue dysfunction 39 
(leptin, adiponectin) and monocyte activation (sCD14 and sCD163) were measured by ELISA. 40 
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Hepatic patterns of macrophage activation were explored with immunohistochemistry. 16s 41 
rRNA sequencing was performed with stool. 42 
Results: Thirty-three cases were included (≥F2 fibrosis n=16), matched to HIV+ (n=29) and 43 
HIV- (n=17) controls. Cases with NAFLD were more obese (BMI 31.0±4.4 kg/m2 vs 24.1 ±2.8 44 
kg/m2 p<0.001) and had significantly increased levels of sCD14, sCD163  and higher leptin to 45 
adiponectin ratio versus HIV+ controls. Cases with ≥F2 verses <F2 fibrosis had increased sCD14 46 
(1.4 ±0.4 vs 1.1 ±0.3 µg/ml, p=0.023) and sCD163 (1.0 ±0.3 vs 0.8 ±0.3 µg/ml, p=0.060) which 47 
correlated with waist circumference  (sCD14 p=0.022, sCD163 p=0.011). 48 
Immunohistochemistry showed increased hepatic portal macrophage clusters in patients 49 
with fibrosis. No markers of bacterial translocation or changes to the microbiome were 50 
associated with NAFLD or fibrosis.  51 
Conclusion: NAFLD fibrosis stage in HIV mono-infected patients is associated with monocyte 52 
activation in the context of obesity, which may be independent of bacterial translocation and 53 
gut microbiome.  54 
Key Words: NAFLD; NASH; fibrosis; HIV; translocation; monocyte. 55 
Introduction 56 
Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease 57 
worldwide with an estimated prevalence of 25%.[1] NAFLD encompasses a spectrum of 58 
disease pathology, ranging from non-alcoholic fatty liver (NAFL) i.e. steatosis without hepatic 59 
injury, to non-alcoholic steatohepatitis (NASH), a more severe entity defined by liver steatosis 60 
with lobular inflammation and hepatocytes ballooning, and fibrosis.[2] Liver fibrosis is the 61 
most important stage of disease progression in NAFLD, as it is the key predictor of increased 62 
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liver-related mortality.[3] Although only a minority of patients with NAFLD will develop 63 
cirrhosis, such is the scale of the problem that NASH is projected to become the leading 64 
indication for liver transplant in the next 5-10 years in developed countries.[4] [5] 65 
NAFLD, NASH and fibrosis in HIV mono-infected subjects have only been investigated with a 66 
limited number of liver biopsy-based analyses.[6][7][8][9]  A recent systematic review by our 67 
group found a prevalence of NAFLD of 35% in populations mainly investigated with imaging 68 
for abnormal liver function tests, and about 20% of patients who had a liver biopsy had 69 
significant fibrosis (>=F2).[10]  70 
Obesity and the metabolic syndrome are strongly associated with NAFLD and progression to 71 
NASH and fibrosis in populations both without[11] [12] and with HIV. [10][13][14][15] In the 72 
non- HIV population this may in part be mediated by a complex interaction of adipose tissue 73 
dysfunction, bacterial translocation and changes to the structure of the gut 74 
microbiome[16][17][18]. However, this has been poorly investigated in patients with HIV. The 75 
loss of gut-associated lymphoid tissue (GALT) following HIV infection, bacterial translocation 76 
and systemic immune activation has been an important paradigm in our understanding of HIV 77 
disease progression,[19] and even in patients established on effective antiretroviral therapy 78 
(ART), restoration of the GALT is slower than the peripheral CD4 cell count. Therefore an 79 
incomplete resolution of the gut mucosal barrier may contribute to persistent immune 80 
activation in these patients,[20] in turn leading to chronic hepatic inflammation and the 81 
development of NASH. Furthermore, research on the gut microbiome has demonstrated 82 
changes associated with HIV infection that may further modulate the host immune 83 
response.[21] Therefore there may be a synergy between HIV and NAFLD driving liver 84 
inflammation and fibrosis. 85 
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Our study aimed to explore the role of bacterial translocation, adipose tissue dysfunction, 86 
immune activation and gut dysbiosis in the development of NAFLD, NASH and fibrosis in HIV 87 
mono-infected patients treated with ART.  88 
Methods 89 
Study Population 90 
Patients were prospectively recruited in clinics specialising in HIV and liver disease at three 91 
main HIV centres in London, UK (Imperial College Healthcare NHS Trust, Chelsea & 92 
Westminster NHS Trust, Royal Free NHS Trust). Controls were prospectively recruited from 93 
the same institutions. 94 
Cases were defined as patients with controlled HIV-1 mono-infection i.e. undetectable viral 95 
load (<50 cp/ml) and CD4 cell count> 200/mm3) on ART and liver biopsy proven NAFLD. 96 
Liver biopsy was performed in cases of persistent ALT≥80 IU/l and/or transient elastography 97 
(Fibroscan®) ≥7.1kPa according to the treating physician’s discretion. Fibroscans were 98 
performed after an overnight fast according to standard protocol as previously described, 99 
reporting data on both liver stiffness and controlled attenuation parameter (CAP).[22] 100 
Exclusion criteria were: patients with alcohol excess within the last 6 months defined as 101 
>21units/week for men and >14units/ week for women; CD4 cell count <200/mm3 and/or 102 
active AIDS- defining illness; other known causes of chronic liver disease (positive HBs antigen 103 
or HCV aŶtiďody, autoiŵŵuŶe disease, ďiliary disease, haeŵoĐhroŵatosis or WilsoŶ’s 104 
disease); current use of steatogenic medication such as methotrexate or long- term steroids.  105 
HIV positive age and sex- matched controls were defined as non-obese subjects with normal 106 
liver function tests on at least two occasions over the last 12 months prior the start of the 107 
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study, alcohol intake less than 21 units per week and no history of liver disease. HIV negative 108 
controls were age, sex and body mass index (BMI)- matched to HIV positive controls. 109 
Metabolic syndrome was defined by established international guidelines.[23] 110 
Histopathology and Immunohistochemistry 111 
Liver biopsies were formalin- fixed and paraffin- embedded. Sections were stained with 112 
trichrome and Haematoxylin & Eosin (H&E) and reported by liver histopathologists blinded to 113 
the study data. NASH was defined as the presence of steatosis with ballooning and lobular 114 
inflammation, and cases were graded according to the NASH Clinical Research Network (CRN) 115 
scoring system.[2] Clinically significant liver fibrosis was defined as at least F2 by the Brunt 116 
criteria (pericellular and periportal fibrosis).[24] 117 
Liver biopsy slides were stained with antibodies for CD14 and CD163 and reviewed at x100 118 
magnification. Clusters were defined as ≥3 positively stained macrophages in a single group. 119 
Clusters were identified as portal or lobular, manually counted and divided by the aggregate 120 
length of the biopsy cores.[25]  121 
Laboratory Assays 122 
Overnight fasted blood samples were drawn in clinic. Serological markers of bacterial 123 
translocation (lipopolysaccharide- binding protein (LBP) (RND Systems, Abingdon, UK) and 124 
lipopolysaccharide (LPS) (Cusabio, Wuhan, China)) and monocyte activation (soluble CD14 125 
(sCD14) and soluble CD163 (sCD163), RND Systems, Abingdon, UK)), inflammatory cytokines 126 
(Interleukin-6 (IL-6) (Life Technologies, Paisley, UK)), tumour necrosis factor alpha receptor 2 127 
(TNFαR2) (RND Systems, Abingdon, UK) ) and adipokines (adiponectin and leptin (Life 128 
Technologies, Carlsbad, USA) ) ǁere ŵeasured ďy ELISA folloǁiŶg the ŵaŶufaĐturer’s 129 
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instructions. Leptin to adiponectin ratio was used as a marker of adipose tissue dysfunction 130 
and insulin resistance.[26][27] 131 
DNA was extracted from whole blood using QIAamp DNA Blood Midi kit (Qiagen Ltd, 132 
Manchester, UK) and bacterial DNA quantified by qPCR as previously reported[28] 133 
(supplementary methods).  134 
 135 
Stool microbial DNA Extraction and 16s rRNA Sequencing 136 
Stool samples were collected at the same time as blood samples or within the following 2 137 
weeks. Faecal DNA extraction was performed as previously described.[29]  138 
Sequencing was performed on an Illumina Miseq instrument (Illumina Inc., Saffron Walden, 139 
UK) using the MiSeq Reagent Kit v3 (Illumina) and paired-end 300bp chemistry. The 16s rRNA 140 
sequencing data generated on MiSeq was processed on Mothur v.1.39.5 using the MiSeq SOP 141 
Pipeline.[30] Further detail is described in the supplementary methods.  142 
Statistical Analysis 143 
Quantitative variables were presented as mean ±SD or median (95% CI) in cases of parametric 144 
and non-parametric distribution respectively. Two- group comparisons of continuous data 145 
were performed using independent sample t-tests for parametric data and Mann-Whitney U 146 
for non-parametric data, and chi-square for proportions. Multiple- group comparisons were 147 
conducted using ANOVA or Kruskall-Wallis tests. Associations between laboratory data and 148 
liver disease classification were explored using logistic regression and bivariate analyses 149 
conducted using biologically relevant variables. Associations between laboratory variables 150 
and obesity were explored using linear regression. P values <0.05 were considered significant. 151 
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Statistical analyses were conducted using GraphPad Prism and IBM SPSS Statistics Software 152 
version 23. Microbiome analysis was conducted on Statistical Analysis of Metagenomic Profiles 153 
(STAMP) and the R statistical package (Supplementary methods). 154 
Results 155 
Characteristics of cases and controls 156 
Thirty-three cases, 29 HIV-positive and 17 HIV-negative controls were included in the study. 157 
The characteristics are described in table 1 and supplementary table 1.  158 
The mean age of cases was 46 ±12.2 years, BMI 31.0±4.4 kg/m2 and waist circumference 159 
104.1±11.4 cm. Twenty-two (66.7%) patients had metabolic syndrome and 5 (15.2%) patients 160 
were on treatment for type 2 diabetes. HIV+ and HIV- healthy controls were 48.3 ±11.0 years 161 
and 48.0 (36.5-53.5) years respectively, and slim (BMI 24.1 ±2.8 kg/m2 and 25.2 ±3.5 kg/m2; 162 
waist circumference 85.7 ±8.0 cm and 86.0 ±7.1 cm).  163 
Nine (27%) patients had non-alcoholic fatty liver (NAFL), and 24 (73%) patients had NASH;17 164 
(51.5%) had none or mild liver fibrosis (F0-1), 3 (9.1%) had significant fibrosis (F2) and 13 165 
(39.4%) advanced fibrosis (F3), including 4 patients with historical liver biopsies but with no 166 
significant weight change since biopsy. No patients had cirrhosis (Supplementary Table 2). 167 
The median time between biopsy and peripheral blood sample collection was 1 month (IQR 168 
0-5).  169 
NAFLD and liver fibrosis are not associated with markers of bacterial translocation 170 
There was no difference either in levels of LBP (5.9 ±2.0 vs 5.3 ±1.7 µg/ml, p=0.330), bacterial 171 
DNA (0.01 ±0.01 vs 0.01 ±0.00 pg/ml, p=0.566) or LPS (30.2 (0.0-63.1) pg/ml vs 11.3 (0.0-49.7) 172 
pg/ml, p=0.269) between NAFLD cases compared to HIV+ controls. There was no difference 173 
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in any of these markers between HIV+ and HIV- controls (Supplementary Figure 1). These 174 
markers of translocation also did not distinguish NASH from NAFL (Supplementary Table 3) or 175 
significant fibrosis (Supplementary Figure 1). 176 
NAFLD and liver fibrosis are associated with monocyte activation and adipose tissue 177 
dysfunction  178 
NAFLD cases had significantly higher levels of sCD14 (1.3 ±0.4 vs 1.1 ±0.4 µg/ml, p=0.031), 179 
sCD163 (0.9 ±0.3 vs 0.7 ±0.2 µg/ml, p=0.002) and leptin (11.8 (3.8-20.2) vs 3.5 (2.1-5.5) ng/ml, 180 
p<0.0001), lower levels of adiponectin (1.1 (0.5-2.4) vs 2.5 (1.1-4.6) µg/ml, p=0.005), and 181 
higher leptin to adiponectin ratio (9.5 (2.5-27.6) vs 1.6 (0.6-4.6), p<0.0001) compared to HIV+ 182 
controls. IL-6 (7.2 ±2.0 vs 7.1 ±1.8 pg/ml, p=0.821) and TNFαR2 (1.1 ±0.5 vs 1.1 ±0.6 ng/ml, 183 
p=0.687) levels did not differ between HIV+ NAFLD cases and HIV+ controls. There was no 184 
difference in any of the markers between HIV+ and HIV- controls (Figure 1 and Supplementary 185 
Table 3). 186 
Cases with F2-F3 fibrosis had significantly higher levels of sCD14 (1.4 ±0.4 vs 1.1 ±0.3 µg/ml, 187 
p=0.023, ANOVA p=0.008) compared to cases with F0-F1 fibrosis (Figure 1), whereas there 188 
was no difference in sCD14 levels between cases with F0-F1 fibrosis compared to HIV+ 189 
controls (1.1 ±0.3 v 1.1 ±0.4 µg/ml, p=0.521). There was a trend to increased sCD163 (1.0 ±0.3 190 
vs 0.8 ±0.3 µg/ml, p=0.060) and leptin to adiponectin ratio (12.2 (7.5-37.3) vs 5.3 (1.8-21.7), 191 
p=0.063) from cases with F0-F1 fibrosis as compared to cases with F2-F3 fibrosis, but a 192 
significant increase in these markers by fibrosis stage compared to controls (ANOVA p=0.001 193 
and p<0.0001 respectively, Figure 1). There was a significant increase in levels of IL-6 in cases 194 
with F2-F3 compared to cases with F0-F1 fibrosis (8.0 ±2.4 vs 6.4 ±1.0 pg/ml, p=0.022), but 195 
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there was no statistical difference in TNFαR2 levels between both groups (1.2 ±0.6 vs 1.0 ±0.4 196 
ng/ml, p=0.341). 197 
Systemic markers of monocyte activation and adipose tissue dysfunction correlate with 198 
central obesity 199 
We next explored the impact of obesity and metabolic disorders on NAFLD and liver fibrosis. 200 
Cases had higher BMI (31.0 ±4.5 vs. 24.1 ±2.8 kg/m2, p<0.001), waist circumference (104.1 201 
±11.4 vs. 85.7 ±8.0 cm, p<0.001), more type 2 diabetes (15% vs. 0% p=0.037), hypertension 202 
(61% vs. 28%, p=0.012) and metabolic syndrome (67% vs. 10%, p<0.001) compared to HIV+ 203 
controls. We correlated markers associated with NAFLD and fibrosis with waist 204 
circumference, a surrogate marker for visceral adiposity. Soluble CD14 (r=0.297, p=0.022), 205 
sCD163 (r=0.413, p=0.001) and leptin to adiponectin ratio (r=0.487, p<0.0001) all positively 206 
correlated with waist circumference (Supplementary Figure 2). Similar results were observed 207 
with BMI, although sCD14 did not reach significance (sCD14 r=0.190, p=0.093; sCD163 208 
r=0.371, p=0.001; leptin to adiponectin ratio r=0.534 p=<0.0001). 209 
Bivariate logistic regression models were used to assess for an association of these markers 210 
with liver fibrosis independent of obesity in all HIV+ subjects (Table 2). Interestingly, sCD14 211 
and sCD163 remained significantly associated with fibrosis when adjusted for BMI (OR 1.003 212 
(1.001-1.005) p=0.016 and OR 1.003 (1.001-1.006) p=0.016) and waist circumference (OR 213 
1.002 (1.000-1.005) p=0.049 and OR 1.003 (1.000-1.006) p=0.034), although the effect was 214 
blunted, whereas the association with leptin to adiponectin ratio was lost.  Age and duration 215 
of ART did not affect the associations of these markers with fibrosis. This suggests that obesity 216 
contributes to but is not the sole factor in the increased monocyte activation associated with 217 
fibrosis.  218 
11 
 
Liver fibrosis is associated with macrophage clustering in the portal tracts 219 
To investigate the relationship between peripheral monocyte activation and intra-hepatic 220 
macrophage activity in HIV-NASH with fibrosis, we performed immunohistochemistry on the 221 
liver tissue (n=28; NASH n=21; ≥F2 fibrosis n=14). Clusters of macrophages in the lobules were 222 
observed in patients with and without fibrosis. However, there were significantly more 223 
CD163- stained portal clusters in ≥F2 versus <F2 fibrosis (0.13 (0.00-0.22) vs 0.0 (0.00-0.04) 224 
clusters/mm, p=0.014), which was not observed with CD14 (0.01 (0.00-0.09)vs 0.00 (0.00-225 
0.02) clusters/mm, p=0.122) (Figure 2), although the overall staining with CD14 was weaker 226 
than with CD163. There was a significant correlation between both sCD163 with CD163-227 
stained portal clusters (r=0.504, p=0.010), and sCD14 with CD14-stained portal clusters 228 
(r=0.431, p=0.029). Neither portal clusters of sCD14 or sCD163 stained macrophages 229 
distinguished NASH from NAFL (CD14 0.00 (0.00-0.06) vs 0.00 (0.00-0.04) clusters/mm, 230 
p=0.492; CD163 0.04 (0.00-0.16) vs 0.00 (0.00-0.06) clusters/mm, p=0.101). 231 
Gut microbiota  232 
NAFLD is not associated with a distinct gut microbial profile 233 
Fifty-seven stool samples (cases n=27/33, HIV+ controls n=20/29, HIV-controls n=10/17) were 234 
analysed using 16s rRNA sequencing. The characteristics of this subpopulation are shown in 235 
Supplementary Table 4. Analysis of the 16s rRNA gene sequencing showed no difference in 236 
the relative abundance of bacteria at all levels of the taxanomic classification between HIV+ 237 
patients with NAFLD and HIV+ controls. Community structures did not differ between groups 238 
on the non- metric multidimensional scaling (NMDS) plot (PERMANOVA p=0.809, 239 
Supplementary Figure 3A). Similarly, there was no distinct microbiota associated with NASH 240 
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or significant fibrosis (PERMANOVA p=0.858 and p=0.093, Supplementary Figure 3B and 241 
Figure 3A).  242 
HIV infection is associated with a Prevotella- enriched enterotype 243 
Given the lack of associations observed within all the HIV positive patients when stratified by 244 
NAFLD, NASH or fibrosis, these patients were grouped and compared to HIV negative controls. 245 
Interestingly, there were marked differences observed in the microbiome of subjects when 246 
stratified by HIV serostatus. NMDS plot demonstrated distinct clustering of microbial 247 
communities according to HIV serostatus (PERMANOVA p=0.001, Figure 3B), which remained 248 
when only HIV+ controls were compared to HIV- controls, confirming this was not a function 249 
of increased BMI or metabolic co-morbidities (data not shown). Significant changes between 250 
the groups emerged at the class level, with significantly higher abundance of Negativicutes 251 
(Mean difference (MD) 7.2% 95%CI 4.9-9.5, corrected p=0.002, Figure 3C). The most striking 252 
feature was an enrichment of Prevotellaceae (MD 28.0% (19.7-35.6), corrected p=0.011) and 253 
Prevotella (MD 25.7% (17.6-33.1), corrected p=0.013) at the family and genus level 254 
respectively. This was associated with an expected depletion in Bacteroidaceae (MD -22.9% 255 
(-15.1- -30.1), corrected p=0.022) and Bacteroides (MD -22.9% (-15.4- -30.3), corrected 256 
p=0.026) compared to HIV- subjects, who are known to compete in the same environmental 257 
niche (Figure 3C and supplementary Figure 4).  258 
 259 
Discussion 260 
We first explored bacterial translocation according to the biopsy-confirmed severity of liver 261 
disease, which has not previously been documented in this population, and found that neither 262 
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LBP,16s rDNA or LPS were associated with NAFLD and liver fibrosis stage. This was in contrast 263 
to a strong association with increased levels of sCD14, which in other studies has been used 264 
as a surrogate marker of bacterial translocation as CD14 is a co-receptor for LPS and is cleaved 265 
from the cell surface of circulating monocytes following activation by LPS.[31] However, 266 
sCD14 is not specific to LPS and may be released following monocyte stimulation by multiple 267 
ligands and as such also represents a non-specific marker of monocyte activation.[31] Given 268 
the lack of association with three other markers of bacterial translocation (LBP, bacterial DNA 269 
and LPS), monocyte activation more likely explains the increased circulating levels of sCD14 270 
in our patients, which is consistent with the increase in sCD163 levels in cases with NAFLD and 271 
fibrosis.  272 
There is an extensive literature supporting a role for bacterial translocation in NAFLD, 273 
although this is predominantly in animal models.[32] Clinical studies have also demonstrated 274 
associations between NAFLD and markers of increased gut permeability, but the results are 275 
more inconsistent.[33][34][35] This may be a function of methodological limitations, with LPS 276 
in particular lacking robust and reproducible assays.[36] However, it may also be that the 277 
absolute levels of systemic bacterial products are much less than in patients with more 278 
advanced liver disease (e.g. decompensated cirrhosis)[37][28] and beyond the limit of 279 
detection, especially when sampled peripherally rather than in portal blood. Moreover, the 280 
similar results between the HIV+ and HIV- control groups suggests there may in fact be 281 
restoration of the gut barrier in patients treated with effective ART.[20] 282 
Biomarkers of monocyte activation in NAFLD have been investigated in both HIV and general 283 
populations. A study from the Multicentre AIDS Cohort Study (HIV+ n=329, NAFLD n=44) 284 
found an association between sCD14 and sCD163 with NAFLD which was lost following 285 
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adjustment for study site, age, race and PNPLA3 genotype. However, cases were defined by 286 
liver steatosis on CT scan rather than biopsy, without stratification by NASH or fibrosis stage, 287 
so a detailed analysis of these markers in progressive disease could not be performed.[38] 288 
Another study in HIV mono-infected patients with or without metabolic syndrome (n=405) 289 
used Fibroscan to stratify by liver fibrosis, and found higher levels of circulating sCD14 and 290 
sCD163 in patients with metabolic syndrome, with sCD163 levels significantly associated with 291 
fibrosis stage independent of metabolic syndrome. Since clinical features of obesity were also 292 
associated with fibrosis stage, the authors concluded adipose tissue dysfunction was 293 
important but not the sole factor in monocyte activation and hepatic fibrogenesis. [13] In the 294 
non-HIV population, a study combining an Australian (n=157) and Italian (n=174) cohort of 295 
biopsy-confirmed NAFLD demonstrated a significant association between serum sCD163 296 
levels and fibrosis stage, obesity and insulin resistance, which remained independently 297 
associated with liver fibrosis after adjustment for metabolic parameters.[25] Overall, these 298 
studies have consistently shown that biomarkers of monocyte activation, especially sCD163, 299 
are strongly linked to but not entirely explained by the metabolic complications of obesity, 300 
and appear to be key players in the development of NAFLD and fibrosis, regardless of HIV 301 
infection. This is consistent with our data:  sCD14, sCD163 and leptin to adiponectin ratio (a 302 
marker of adipose tissue dysfunction and insulin resistance)[26] increased with fibrosis stage 303 
and significantly correlated with waist circumference, but the association between sCD14 and 304 
sCD163 with fibrosis remained after adjustment for waist circumference.   305 
To investigate the link between peripheral markers of monocyte activation and intra-hepatic 306 
macrophages we performed immunohistochemistry in the liver tissue.  CD163 - stained portal 307 
tract clusters of activated macrophages increased in patients with significant liver fibrosis 308 
(≥FϮͿ. This pattern was not so clearly seen with CD14, although the staining was weaker 309 
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throughout the biopsy suggesting it may be a less sensitive marker. Previous studies in non-310 
HIV patients have found clustering of CD163-stained macrophages in NASH compared to NAFL 311 
patients, although they did not distinguish portal from lobular clusters, or look specifically at 312 
fibrosis.[25][39]  313 
Here, the immunohistochemistry data, which significantly correlated with peripheral 314 
markers, further supports the notion that monocyte-macrophage activation is associated with 315 
progressive fibrosis stage, and the marked differences in peripheral markers between cases 316 
and controls is not solely a reflection of obesity rates in the groups.  However, the 317 
demographic data clearly also highlights how obesity is an important contributor. This is 318 
consistent with experimental studies mechanistically linking central obesity to NASH in a 319 
disease model where inflamed, insulin resistant adipose tissue enriched with activated 320 
macrophages secretes leptin and other pro-inflammatory cytokines into the systemic 321 
circulation, in turn stimulating hepatic immune cell infiltration and fibrogenesis.[16] However, 322 
additional triggers independent of obesity such as hepatocyte injury from lipotoxicity and 323 
oxidative stress may also contribute to local monocyte activation.[40] Therefore, targeting 324 
monocyte recruitment is an emerging therapeutic option in NASH clinical trials;  a phase 3 325 
trial is underway evaluating Cenicriviroc, a CCR2/CCR5 antagonist targeting chemokine 326 
signalling important for monocyte infiltration and activation (NCT 03028740),[41] and 327 
similarly an early proof-of-concept trial is investigating the potential benefit of Maraviroc, a 328 
CCR5 receptor antagonist and licensed antiretroviral, in HIV-associated NASH 329 
(ISRCRN15410818).[42] 330 
The role of the gut microbiome in NAFLD pathogenesis is an area of significant research 331 
interest, and its role in mediating complex metabolic and inflammatory pathways influencing 332 
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the development of NASH has been elegantly demonstrated in many pre-clinical models, 333 
opening new avenues for possible therapeutic targets.[17] However, human studies have 334 
often produced inconsistent results.[32] Our study has not observed an association between 335 
markers of bacterial translocation or the microbiota with NAFLD, NASH or fibrosis, contrasting 336 
with previous studies in the non-HIV population of patients with NAFLD.[43] This may reflect 337 
our small sample size, but the fact that associations of specific bacterial populations with 338 
NAFLD are rarely repeated in subsequent studies[44] demonstrates the difficulty in exploring 339 
a highly complex system in a disease that is slow to evolve.  340 
One striking finding was the significant difference in gut microbial communities between 341 
cases with HIV and age and sex- matched healthy controls. This was driven principally by an 342 
enrichment in the genus Prevotella (family Prevotellaceae), mirrored by a converse depletion 343 
of its competitor Bacteroides. Interestingly, Prevotella enrichment has been a relatively 344 
consistent finding in previous studies investigating the impact of the microbiome in people 345 
living with HIV, although this may be a function of lifestyle factors, particularly sexual 346 
practices, rather than HIV infection per se.[45] The reasons for this are incompletely 347 
understood but may be linked to local environmental perturbations associated with 348 
microtrauma and tissue healing.[46] Further mechanistic work is required to investigate a 349 
possible role for Prevotella in muĐosal healiŶg, aŶd ǁhether this affeĐts aŶ iŶdiǀidual’s 350 
susceptibility to acquiring HIV infection. 351 
Our study has some limitations. First, the small sample size. The gold standard for diagnosing 352 
NASH and fibrosis remains liver biopsy, an invasive procedure and currently only indicated in 353 
patients who meet specific criteria following assessment with non-invasive markers. This 354 
limits the sample size,  restricts analyses to an enriched group with few cases of mild liver 355 
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disease, and some smaller associations with specific biomarkers may have been missed by 356 
lack of statistical power. This may explain why none of the biomarkers could distinguish NASH 357 
from NAFL, and negative results in the microbiota analysis. However, there is currently no 358 
validated diagnostic marker of NASH, and non-invasive markers have not been well validated 359 
in the HIV population, therefore a small study with well-characterised liver histology might be 360 
superior to larger studies based on non-invasive markers when investigating mechanisms of 361 
NAFLD. Second, some of the results may have been a function of the control group selection, 362 
whose BMI was much lower than the cases. However, our bivariate analysis demonstrated an 363 
association of monocyte markers independent of BMI and waist circumference. Finally, we 364 
were unable to collect Fibroscan values in HIV+ and HIV- controls. However, all had exclusion 365 
of acute or chronic liver disease and normal liver function tests and biochemistry. 366 
In conclusion, monocyte activation associated with central obesity seems to be a key player 367 
in the development of NAFLD and significant liver fibrosis in HIV mono-infected patients 368 
independent of dysbiosis and gut translocation.  369 
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Table 1 521 
Parameters 
Cases 
n=33 
HIV+ 
Controls 
n=29 
HIV- Controls 
n=17 
P value* 
Age (years) 46.4 (12.4) 48.3 (11.0) 48.0 (36.5-53.5) 0.523 
Male Gender (%) 32 (97.0) 29 (100) 15 (88.2) 0.525 
Ethnicity 
Caucasian (%) 
Black (%) 
Asian (%) 
Other (%) 
 
27 (81.8) 
2 (6.1) 
3 (9.1) 
1 (3.0) 
 
22 (75.9) 
3 (10.3) 
2 (6.9) 
2 (6.9) 
 
10 (58.8) 
0 (0.0) 
5 (29.4) 
2 (11.8) 
 
0.756 
0.658 
1.000 
0.595 
Transmission Risk Factor 
MSM (%) 
Heterosexual (%) 
Vertical Transmission (%) 
                   
30 (90.9) 
2 (6.1) 
1 (3.0) 
29 (100) 
0 (0) 
0 (0) 
0 (0.0) 
17 (0.0) 
N/A 
0.241 
0.494 
1.00 
BMI (kg/m2) 31.0 (4.5) 24.1 (2.8) 25.2 (3.5) <0.001* 
Waist circumference (cm) 104.1 (11.4) 85.7 (8.0) 86.0 (7.1) <0.001* 
Type 2 Diabetes (%) 1 5 (15.2) 0 (0) 0 (0) 0.037* 
Hypertension (%) 2 22 (66.7) 9 (31.0) 0 (0) 0.010* 
High serum Triglycerides (%) 3 22 (66.7) 8 (27.6) 0 (0) 0.003* 
Low serum HDL (%) 4 22 (66.7) 9 (31.0) 0 (0) 0.010* 
Metabolic Syndrome 5 22 (66.7) 3 (10.3) 0 (0) <0.001* 
Time since HIV Diagnosis 
(years) 
9.0 (5.0-15.0) 12.0 (5.5-
18.5) 
N/A 0.385 
CD4 cell count Nadir 262.1 (168.4) 292.5 (225.7) N/A 0.536 
Duration ART (years) 7.6 (6.5) 10.2 (8.0) N/A 0.221 
Cumulative duration of ART 
Class (years) 
    
NRTI  8.2 (6.5) 20.3 (8.0) N/A 0.290 
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NNRTI  4.6 (4.6) 6.4 (6.9) N/A 0.233 
PI  0.0 (0.0-3.8) 0.0 (0.0-2.3) N/A 0.584 
II  0.0 (0.0-1.2) 0.0 (0.0-0.0) N/A 0.027* 
ALT (IU/L) 104.7 (62.1) 28.3 (8.3) - <0.001* 
AST (IU/L) 56.9 (42.0-
59.5) 
27.8 (24.0-
31.0) 
- 0.002* 
ALP (IU/ml) 91.1 (25.1) 76.4 (16.3) - 0.011* 
Cholesterol (mmol/L) 5.0 (0.9) 4.8 (1.4) - 0.617 
LDL (mmol/L) 3.1 (1.1) 3.0 (1.1) - 0.795 
HDL (mmol/L) 1.3 (1.2) 1.3 (0.4) - 0.873 
Triglycerides (mmol/L) 2.2 (1.1) 1.5 (0.8) - 0.011* 
Glucose (mmol/L) 5.4 (1.2) 5.0 (0.8) - 0.253 
CD4 (cells/mm3) 815.5 (309.2) 765.7 (235.1) - 0.506 
CD8 (cells/mm3) 1048.8 (417.3) 830.8 (317.0) - 0.046* 
Liver Stiffness (kPa) 8.7 (3.7) - - - 
CAP (dB/min) 308.8 (36.2) - - - 
 522 
Table 1: Demographic data of cases compared to age- and sex- matched HIV+ and HIV- 523 
controls. Categorical variables are expressed as raw numbers and percentages, continuous 524 
variables are reported as mean (SD) or median (IQR). 1 Active treatment with anti-diabetic 525 
medications; 2 SystoliĐ BP ≥ϭϯϬŵŵHg, diastoliĐ BP ≥85ŵŵHg or aĐtiǀe treatŵeŶt aŶti-526 
hypertensive medication; 3 Serum triglycerides >1.7mmol/L or active treatment with a fibrate; 527 
4 Serum HDL < 1.0 or active treatment with a statin. 5As per international guidelines.[23] 528 
*Cases vs HIV+ controls, P value<0.05. MSM: men who have sex with men; BMI: body mass 529 
index; HDL: high density lipoprotein; LDL: low density lipoprotein; ART: antiretroviral therapy; 530 
NRTI: nucleoside reverse transcriptase inhibitors; NNRTI: non-nucleoside reverse 531 
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transcriptase inhibitors; PI: protease inhibitors; II: integrase inhibitors; ALT: alanine 532 
aminotransferase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; CAP: 533 
controlled attenuation parameter. 534 
 535 
 536 
 537 
 538 
 539 
 540 
 541 
 542 
 543 
 544 
 545 
 546 
 547 
 548 
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Table 2: Odds ratios for sCD14, sCD163 (per 1ng/ml increase) and leptin to adiponectin 
ratio as biomarkers for significant fibrosis in all subjects with HIV (n=62), adjusted for 
either age, waist circumference, BMI or duration of antiretroviral therapy (ART). Italics 
indicate p<0.05. 
 
Figure Legends 
 
Figure 1: Markers of monocyte activation and adipose tissue function in cases and controls.  A-E: 
NAFLD; F-J: sub-categorised by fibrosis stage. sCD14: soluble CD14; sCD163: soluble CD163. 
Figure 2: Liver immunohistochemistry. A-B: Sample liver sections (Magnification x100) without (A) 
     
Biomarker Unadjusted OR P Value Model Adjusted OR for 
NAFLD (95% CI)
P Value
sCD14 1.003 (1.001-
1.005) 
0.006 +Age 1.003 (1
1.005) 
 
  +Waist Circumference 1.002 (1
1.005) 
 
  +BMI 1.003 (1
1.005) 
   + Duration of ART 1.003 (1.
1.005) 
sCD163 1.004 (1.001-
1.006) 
0.003 +Age 1.003 (1
1.006 
 
  +Waist Circumference 1.003 (1
1.006) 
 
  +BMI 1.003 (1
1.006) 
   + Duration of ART 1.003 (1
1.006) 
Leptin:Adiponectin 1.059 (1.016-
1.104) 
0.007 +Age 1.057 (1.
1.101) 
   +Waist Circumference 1.034 (
1.081) 
   +BMI 1.033 (
1.081) 
   + Duration of ART 1.061 (1
1.108) 
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and with (B, arrow) portal clusters of CD163-stained macrophages; C-D: Portal clusters/mm liver 
tissue with CD163 (C) and CD14 (D) staining; E-F: Correlation between liver portal macrophage 
clusters and peripheral markers of monocyte activation. 
Figure 3:  Gut microbial communities in liver fibrosis and HIV infection. Non-metric dimensional 
scaling (NMDS) plot comparing microbial community structures between A). HIV positive cases 
with NAFLD and ≥FϮ Fiďrosis ǀs NAFLD aŶd <FϮ Fiďrosis ǀs HIV+ ĐoŶtrols. PERMANOVA p=Ϭ.093; B). 
HIV+ (all) vs HIV- subjects. PERMANOVA p=0.001. C). Extended error bar plots comparing the mean 
difference of significantly altered proportions at Class, Order, Family and Genus taxonomic 
classification between HIV+ subjects vs HIV- subjects ;White’s ŶoŶ-parametric t-test with 
Benjamini-Hochberg FDR correction). 
 
